1 Ocak 2018 Dergi makalesi Açık Erişim

Tasyurek, Hale M.; Eksi, Yunus E.; Sanlioglu, Ahter D.; Altunbas, Hasan A.; Balci, Mustafa K.; Griffith, Thomas S.; Sanlioglu, Salih

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/30547</identifier>
  <creators>
    <creator>
      <creatorName>Tasyurek, Hale M.</creatorName>
      <givenName>Hale M.</givenName>
      <familyName>Tasyurek</familyName>
      <affiliation>Akdeniz Univ Hosp, Human Gene &amp; Cell Therapy Ctr, TR-07058 Antalya, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Eksi, Yunus E.</creatorName>
      <givenName>Yunus E.</givenName>
      <familyName>Eksi</familyName>
      <affiliation>Akdeniz Univ Hosp, Human Gene &amp; Cell Therapy Ctr, TR-07058 Antalya, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Sanlioglu, Ahter D.</creatorName>
      <givenName>Ahter D.</givenName>
      <familyName>Sanlioglu</familyName>
      <affiliation>Akdeniz Univ Hosp, Human Gene &amp; Cell Therapy Ctr, TR-07058 Antalya, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Altunbas, Hasan A.</creatorName>
      <givenName>Hasan A.</givenName>
      <familyName>Altunbas</familyName>
      <affiliation>Akdeniz Univ, Div Endocrinol &amp; Metab, Dept Internal Med, Fac Med, TR-07058 Antalya, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Balci, Mustafa K.</creatorName>
      <givenName>Mustafa K.</givenName>
      <familyName>Balci</familyName>
      <affiliation>Akdeniz Univ, Div Endocrinol &amp; Metab, Dept Internal Med, Fac Med, TR-07058 Antalya, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Griffith, Thomas S.</creatorName>
      <givenName>Thomas S.</givenName>
      <familyName>Griffith</familyName>
      <affiliation>Univ Minnesota, Sch Med, Dept Neurol, Minneapolis, MN 55455 USA</affiliation>
    </creator>
    <creator>
      <creatorName>Sanlioglu, Salih</creatorName>
      <givenName>Salih</givenName>
      <familyName>Sanlioglu</familyName>
      <affiliation>Akdeniz Univ Hosp, Human Gene &amp; Cell Therapy Ctr, TR-07058 Antalya, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Hiv-Based Lentivirus-Mediated Vasoactive Intestinal Peptide Gene Delivery Protects Against Dio Animal Model Of Type 2 Diabetes</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2018</publicationYear>
  <dates>
    <date dateType="Issued">2018-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/30547</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1038/s41434-018-0011-1</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Type 2 diabetes mellitus (T2DM) is characterised by insulin resistance, glucose intolerance and beta cell loss leading to hyperglycemia. Vasoactive intestinal peptide (VIP) has been regarded as a novel therapeutic agent for the treatment of T2DM because of its insulinotropic and anti-inflammatory properties. Despite these beneficial properties, VIP is extremely sensitive to peptidases (DPP-4) requiring constant infusion or multiple injections to observe any therapeutic benefit. Thus, we constructed an HIV-based lentiviral vector encoding human VIP (LentiVIP) to test the therapeutic efficacy of VIP peptide in a diet-induced obesity (DIO) animal model of T2DM. VIP gene expression was shown by immunocytochemistry (ICC) and VIP peptide secretion was confirmed by ELISA both in HepG2 liver and MIN6 pancreatic beta cell lines. Functional properties of VIP were demonstrated by cAMP production assay and glucose-stimulated insulin secretion test (GSIS). Intraperitoneal (IP) delivery of LentiVIP vectors into mice significantly increased serum VIP concentrations compared to control mice. Most importantly, LentiVIP delivery in DIO animal model of T2DM resulted in improved insulin sensitivity, glucose tolerance and protection against STZ-induced diabetes in addition to reduction in serum triglyceride/cholesterol levels. Collectively, these data suggest LentiVIP delivery should be evaluated as an experimental therapeutic approach for the treatment of T2DM.</description>
  </descriptions>
</resource>